These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 31116180)

  • 21. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
    Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S
    Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers.
    Booy R; Nolan T; Reynolds G; Richmond P; Nissen M; Marshall H; Stoney T; Van Der Wielen M; Kolhe D; Miller JM
    Pediatr Infect Dis J; 2015 Dec; 34(12):1379-84. PubMed ID: 26372451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
    Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2012 Dec; 8(12):1892-903. PubMed ID: 23032159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
    Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
    BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
    Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
    Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months.
    Díez-Domingo J; Cantarino MV; Torrentí JM; Sansano MI; Rosich AJ; Merino AH; de Miguel AG; González JB; Marcos MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):148-52. PubMed ID: 19927040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
    Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
    Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
    Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
    Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
    Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.
    Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Miller JM
    Vaccine; 2015 Feb; 33(7):933-41. PubMed ID: 25152325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial.
    Knuf M; Rämet M; Breinholt Stærke N; Bertrand-Gerentes I; Thollot Y; B'Chir S; Arroum H; Oster P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052657. PubMed ID: 35445641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age.
    Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Heron L; Lambert S; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2011 Apr; 30(4):340-2. PubMed ID: 21068692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
    Pace D; Snape M; Westcar S; Oluwalana C; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
    Arch Dis Child; 2008 Nov; 93(11):963-70. PubMed ID: 18463125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
    Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
    Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
    Pace D; Khatami A; Attard-Montalto S; Voysey M; Finn A; Faust SN; Heath PT; Borrow R; Snape MD; Pollard AJ
    Vaccine; 2016 Dec; 34(50):6350-6357. PubMed ID: 28029540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
    Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
    Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants.
    Klein NP; Abu-Elyazeed R; Baine Y; Cheuvart B; Silerova M; Mesaros N
    Hum Vaccin Immunother; 2019; 15(2):327-338. PubMed ID: 30252603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
    Ostergaard L; Lebacq E; Poolman J; Maechler G; Boutriau D
    Vaccine; 2009 Jan; 27(1):161-8. PubMed ID: 18834910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
    Khatami A; Snape MD; Wysocki J; John TM; Westcar S; Mesaros N; Peddiraju K; Boutriau D; Yu LM; Pollard AJ
    Pediatr Infect Dis J; 2012 Oct; 31(10):1069-73. PubMed ID: 22673139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.